Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.
Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer's disease than those receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results